Market Overview:
The global intravenous immunoglobulin (IVIg) market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The growth in the market can be attributed to factors such as rising prevalence of autoimmune diseases, increasing number of acute infections and growing demand for IVIg products in emerging countries. Based on type, the global IVIg market is segmented into liquid and powder forms. The liquid form segment is expected to account for a larger share of the market during the forecast period. This can be attributed to its ease of use and better patient compliance as compared to powder form products. Based on application, the global IVIg market is segmented into immunodeficiency disorders, autoimmune diseases and acute infections. Immunodeficiency disorders are estimated to account for a larger share of the market during the forecast period owing to rising incidence rates across all regions globally. Autoimmune diseases are also estimated to grow at a fast pace over next few years due high prevalence rates coupled with technological advancements in this field that have led to development new therapies/treatments options being available in this space currently or soon-to-be launched products). Acute infections are also projected grow at a healthy rate over next few years due high incidence rates coupled with technological advancements that have led increased adoption rate by healthcare professionals globally).
Product Definition:
Intravenous Immunoglobulin (IVIg) is a blood product made from the pooled plasma of thousands of healthy donors. It contains high levels of antibodies (immunoglobulins) which help to fight infection.
-Autoimmune diseases such as Guillain-Barre Syndrome, Myasthenia Gravis.
-Severe infections such as meningitis, sepsis.
IVIg Liquid:
IVIg is a protein-based immunoglobulin that is intravenously administered to patients suffering from immune thrombocytopenic purpura (ITP), chronic idiopathic thrombocytopenic purpura (CITP), acute normothermic phobia (ANPP) or chronic granulomatous disease (CGD). It helps in the treatment of these diseases by enhancing the patient’s own immune response.
IVIg Powder:
IVIg is a protein made by plasma cells and is used to treat immune system disorders. It's also known as intravenous immunoglobulin or IVIG, which helps the body fight against infections and diseases. The most common disease that requires IVIG treatment includes lupus, rheumatoid arthritis, scleroderma, and sclerosis (SLE).
Application Insights:
Based on application, the global IVIg market has been segmented into immunodeficiency diseases, autoimmune disease, acute infection and others. Immunodeficiency diseases dominated the overall industry with a share of over 60.0% in 2017 owing to high product usage in treating immunodeficiency disorders such as acquired immune deficiency syndrome (AIDS). The use of IVIg is beneficial in reducing mortality and morbidity associated with AIDS. Moreover, it helps reduce the risk of transmission of HIV by enhancing CD4+ T-cell count and reducing viral load among antiretroviral-na¢â‚¬â„¢ve individuals.
The acute infection segment is expected to witness lucrative growth during the forecast period due to rising incidences of hospital-acquired infections (HAIs) worldwide coupled with an increase in R&D for developing new products for treatment purposes.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of manufacturers and suppliers coupled with high awareness levels among patients is anticipated to drive the regional market over the forecast period. Increasing incidence of chronic diseases, rising prevalence of immunodeficiency disorders, and increasing government initiatives are some factors expected to boost IVIg demand in North America during the forecast period.
Asia Pacific is estimated to be one of fastest-growing regions during the same period owing to growing healthcare expenditure levels, improving economic conditions & increasing patient disposable income resulting from rapid urbanization & industrialization in emerging countries such as China.
Growth Factors:
- Increasing incidence of autoimmune diseases: The global prevalence of autoimmune diseases is increasing at a significant rate. This is expected to drive the demand for IVIg products in the coming years.
- Growing awareness about the benefits of IVIg therapy: There is growing awareness among healthcare professionals and patients about the benefits of using IVIg products for various indications. This is likely to boost demand for these products in the coming years.
- Technological advancements in manufacturing process: The manufacturers are making continuous efforts to improve the manufacturing process and develop new and innovative products that can meet the needs of patients worldwide. This is likely to propel growth of this market in future years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Intravenous Immunoglobulin (IVIg) Market Research Report
By Type
IVIg Liquid, IVIg Powder
By Application
Immunodeficiency, Autoimmune Disease, Acute Infection
By Companies
Baxter, Grifols, CSL, Octapharma, Biotest, Kedrion, Hualan Bio, CNBG, Shanghai RAAS, CBPO, LFB Group, BPL, Sichuan Yuanda Shuyang
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Intravenous Immunoglobulin (IVIg) Market Report Segments:
The global Intravenous Immunoglobulin (IVIg) market is segmented on the basis of:
Types
IVIg Liquid, IVIg Powder
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Immunodeficiency, Autoimmune Disease, Acute Infection
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Baxter
- Grifols
- CSL
- Octapharma
- Biotest
- Kedrion
- Hualan Bio
- CNBG
- Shanghai RAAS
- CBPO
- LFB Group
- BPL
- Sichuan Yuanda Shuyang
Highlights of The Intravenous Immunoglobulin (IVIg) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- IVIg Liquid
- IVIg Powder
- By Application:
- Immunodeficiency
- Autoimmune Disease
- Acute Infection
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Intravenous Immunoglobulin (IVIg) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Intravenous immunoglobulin (IVIg) is a type of medication that helps the body fight infections. IVIg is given through a vein into the bloodstream. It can be used to treat various types of infections, including hepatitis B and C, human immunodeficiency virus (HIV), and other cancers.
Some of the major companies in the intravenous immunoglobulin (ivig) market are Baxter, Grifols, CSL, Octapharma, Biotest, Kedrion, Hualan Bio, CNBG, Shanghai RAAS, CBPO, LFB Group, BPL, Sichuan Yuanda Shuyang.
The intravenous immunoglobulin (ivig) market is expected to grow at a compound annual growth rate of 5.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Intravenous Immunoglobulin (IVIg) Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Intravenous Immunoglobulin (IVIg) Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Intravenous Immunoglobulin (IVIg) Market - Supply Chain
4.5. Global Intravenous Immunoglobulin (IVIg) Market Forecast
4.5.1. Intravenous Immunoglobulin (IVIg) Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Intravenous Immunoglobulin (IVIg) Market Size (000 Units) and Y-o-Y Growth
4.5.3. Intravenous Immunoglobulin (IVIg) Market Absolute $ Opportunity
5. Global Intravenous Immunoglobulin (IVIg) Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Intravenous Immunoglobulin (IVIg) Market Size and Volume Forecast by Type
5.3.1. IVIg Liquid
5.3.2. IVIg Powder
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Intravenous Immunoglobulin (IVIg) Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Intravenous Immunoglobulin (IVIg) Market Size and Volume Forecast by Application
6.3.1. Immunodeficiency
6.3.2. Autoimmune Disease
6.3.3. Acute Infection
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Intravenous Immunoglobulin (IVIg) Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Intravenous Immunoglobulin (IVIg) Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Intravenous Immunoglobulin (IVIg) Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Intravenous Immunoglobulin (IVIg) Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Intravenous Immunoglobulin (IVIg) Demand Share Forecast, 2019-2026
9. North America Intravenous Immunoglobulin (IVIg) Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Intravenous Immunoglobulin (IVIg) Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Intravenous Immunoglobulin (IVIg) Market Size and Volume Forecast by Application
9.4.1. Immunodeficiency
9.4.2. Autoimmune Disease
9.4.3. Acute Infection
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Intravenous Immunoglobulin (IVIg) Market Size and Volume Forecast by Type
9.7.1. IVIg Liquid
9.7.2. IVIg Powder
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Intravenous Immunoglobulin (IVIg) Demand Share Forecast, 2019-2026
10. Latin America Intravenous Immunoglobulin (IVIg) Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Intravenous Immunoglobulin (IVIg) Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Intravenous Immunoglobulin (IVIg) Market Size and Volume Forecast by Application
10.4.1. Immunodeficiency
10.4.2. Autoimmune Disease
10.4.3. Acute Infection
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Intravenous Immunoglobulin (IVIg) Market Size and Volume Forecast by Type
10.7.1. IVIg Liquid
10.7.2. IVIg Powder
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Intravenous Immunoglobulin (IVIg) Demand Share Forecast, 2019-2026
11. Europe Intravenous Immunoglobulin (IVIg) Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Intravenous Immunoglobulin (IVIg) Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Intravenous Immunoglobulin (IVIg) Market Size and Volume Forecast by Application
11.4.1. Immunodeficiency
11.4.2. Autoimmune Disease
11.4.3. Acute Infection
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Intravenous Immunoglobulin (IVIg) Market Size and Volume Forecast by Type
11.7.1. IVIg Lquid
11.7.2. IVIg Powder
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Intravenous Immunoglobulin (IVIg) Demand Share, 2019-2026
12. Asia Pacific Intravenous Immunoglobulin (IVIg) Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Intravenous Immunoglobulin (IVIg) Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Intravenous Immunoglobulin (IVIg) Market Size and Volume Forecast by Application
12.4.1. Immunodeficiency
12.4.2. Autoimmune Disease
12.4.3. Acute Infection
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Intravenous Immunoglobulin (IVIg) Market Size and Volume Forecast by Type
12.7.1. IVIg Liquid
12.7.2. IVIg Powder
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Intravenous Immunoglobulin (IVIg) Demand Share, 2019-2026
13. Middle East & Africa Intravenous Immunoglobulin (IVIg) Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Intravenous Immunoglobulin (IVIg) Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Intravenous Immunoglobulin (IVIg) Market Size and Volume Forecast by Application
13.4.1. Immunodeficiency
13.4.2. Autoimmune Disease
13.4.3. Acute Infection
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Intravenous Immunoglobulin (IVIg) Market Size and Volume Forecast by Type
13.7.1. IVIg Liquid
13.7.2. IVIg Powder
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Intravenous Immunoglobulin (IVIg) Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Intravenous Immunoglobulin (IVIg) Market: Market Share Analysis
14.2. Intravenous Immunoglobulin (IVIg) Distributors and Customers
14.3. Intravenous Immunoglobulin (IVIg) Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Baxter
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Grifols
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. CSL
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Octapharma
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Biotest
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Kedrion
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Hualan Bio
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. CNBG
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Shanghai RAAS
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. CBPO
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. LFB Group
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. BPL
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Sichuan Yuanda Shuyang
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook